Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
On January 4, 2021, Selecta Biosciences (NASDAQ: SELB) announced participation in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Carsten Brunn, Ph.D., and CFO Brad Dahms will present at the event, which will be available on-demand starting January 11 at 6 a.m. EST. Selecta is known for its ImmTOR™ platform aimed at developing therapies that reduce unwanted immune responses. Their first clinical trial is set for early 2021, targeting methylmalonic acidemia in partnership with AskBio.
- None.
- None.
WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 6 a.m. EST on Monday, January 11, 2021.
A webcast will also be available in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com
FAQ
What is Selecta Biosciences participating in from January 11-14, 2021?
Who are the key executives presenting for Selecta Biosciences?
When will Selecta's presentation be available on-demand?
What is the focus of Selecta's ImmTOR™ platform?
What clinical trial is Selecta Biosciences planning for early 2021?
